04/15/2026
๐จ The FDA is taking a step toward restoring access to key peptides.
12 peptides are being removed from Category 2 and advanced for formal review.
What this means:
๐ฌ Independent evaluation using clinical and safety data
๐งช Potential pathway back to regulated compounding
โ๏ธ Greater oversight and quality control
Why it matters:
โ ๏ธ Prior restrictions pushed some patients toward unregulated sources
๐ This shift supports safer, clinician-guided care
This moves peptide therapy back into a more transparent, regulated process.
At and , peptide therapy is delivered through physician-guided protocols โ designed to support recovery, metabolism, body composition, and long-term health. ๐ค